Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03284333 · ClinicalTrials.gov registry record · NA

enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars

A NA study of Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by Cutera.

Completed
Registry status
NA
Development phase
45
Enrollment target
2
Study locations

NCT03284333 is a NA study of Acne Scars - Mixed Atrophic and Hypertrophic that has completed, run by Cutera. The registered enrollment target is 45 participants, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03284333, a NA study of Acne Scars - Mixed Atrophic and Hypertrophic, has completed, sponsored by Cutera.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.

Interventions

  • DEVICE other

Study Locations (2)

California

  • Cutera Research Center - Brisbane

New York

  • Sadick Dermatology/Sadick Research Center - New York

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2017-07-27
Est. Completion 2018-09-05
Phase NA

Sponsor

Cutera

37 total trials

What the Registry Record Tells You About NCT03284333

The ClinicalTrials.gov registry entry for NCT03284333 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (57% lower). The listed sponsor is Cutera, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Scars - Mixed Atrophic and Hypertrophic appearing as the primary indexed condition, and to 1 intervention - of which other is the first listed.

NCT03284333 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT03284333 about?

NCT03284333 is a clinical study titled "enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars". The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.

What is the current status of trial NCT03284333?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-07-27. Estimated completion is 2018-09-05.

What conditions does trial NCT03284333 study?

This clinical trial studies the following conditions: Acne Scars - Mixed Atrophic and Hypertrophic.

What interventions are being tested in trial NCT03284333?

The interventions under investigation include: other (DEVICE).

Who is sponsoring clinical trial NCT03284333?

This trial is sponsored by Cutera, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03284333 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne Scars - Mixed Atrophic and Hypertrophic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.